{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:00:51Z","timestamp":1792497651590,"version":"4.5.0"},"reference-count":111,"publisher":"Informa UK Limited","issue":"28","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.2217\/fon-2021-0556","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T11:57:47Z","timestamp":1627905467000},"page":"3691-3704","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Pragmatic Patient Engagement in Designing Pragmatic Oncology Clinical Trials"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-9338","authenticated-orcid":false,"given":"Bernard Bright","family":"Davies-Teye","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Health Services Research,University of Maryland School of Pharmacy,\rBaltimore,\rMD\r21201,\rUSA"},{"name":"The PATIENTS Program, University of Maryland,\rBaltimore,\rMD\r21201,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5303-5280","authenticated-orcid":false,"given":"Michelle","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Services Research,University of Maryland School of Pharmacy,\rBaltimore,\rMD\r21201,\rUSA"},{"name":"The PATIENTS Program, University of Maryland,\rBaltimore,\rMD\r21201,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Chauhan","sequence":"additional","affiliation":[{"name":"The PATIENTS Program, University of Maryland,\rBaltimore,\rMD\r21201,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7914-1871","authenticated-orcid":false,"given":"Claudia Rose","family":"Baquet","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Services Research,University of Maryland School of Pharmacy,\rBaltimore,\rMD\r21201,\rUSA"},{"name":"The PATIENTS Program, University of Maryland,\rBaltimore,\rMD\r21201,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4322-2490","authenticated-orcid":false,"given":"C Daniel","family":"Mullins","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Services Research,University of Maryland School of Pharmacy,\rBaltimore,\rMD\r21201,\rUSA"},{"name":"The PATIENTS Program, University of Maryland,\rBaltimore,\rMD\r21201,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2147"},{"issue":"1","key":"e_1_3_2_4_1","first-page":"1","article-title":"From bench to bedside: the growing use of translational research in cancer medicine","volume":"2","author":"Goldblatt EM","year":"2010","unstructured":"Goldblatt EM , LeeWH. From bench to bedside: the growing use of translational research in cancer medicine. Am. J. Transl. Res.2(1), 1\u201318 (2010).","journal-title":"Am. J. Transl. Res."},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.3943"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.12841"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.442"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmx013"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1023-4"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju051"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.01.001"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.01.012"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.009"},{"key":"e_1_3_2_14_1","first-page":"28","article-title":"Models of Engagement: Patients as Partners in Clinical Research","volume":"8","author":"Uhlenbrauck G","year":"2018","unstructured":"Uhlenbrauck G , SchulmanJ, JerniganK, McAdamsP, SinglerL. Models of Engagement: Patients as Partners in Clinical Research. Appl. Clin. Trials8, 28 (2018).","journal-title":"Appl. Clin. Trials"},{"key":"e_1_3_2_15_1","article-title":"Bridging the gap for better patient engagement","author":"Calaprice-Whitty D","year":"2017","unstructured":"Calaprice-Whitty D , ByrneJ, GilbertJ. Bridging the gap for better patient engagement. Appl. Clin. Trials (2017). https:\/\/www.appliedclinicaltrialsonline.com\/view\/bridging-gap-better-patient-engagement.","journal-title":"Appl. Clin. Trials"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291709992285"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0129"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.2012.0155"},{"issue":"39","key":"e_1_3_2_19_1","first-page":"1","article-title":"An evidence base to optimise methods for involving patient and public contributors in clinical trials: a mixed-methods study","volume":"3","author":"Gamble C","year":"2015","unstructured":"Gamble C , DudleyL, AllamA, BellP. An evidence base to optimise methods for involving patient and public contributors in clinical trials: a mixed-methods study. NIHR Journals Libr.3(39), 1\u2013170 (2015).","journal-title":"NIHR Journals Libr."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-019-0163-1"},{"key":"e_1_3_2_21_1","unstructured":"Patient-Centered Outcome Research Institute . \u2018The Value of Engagement\u2019 (2018). https:\/\/www.pcori.org\/engagement\/value-engagement."},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1301"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-014-0617-y"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10742-018-0192-5"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0250-0"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-020-00175-7"},{"issue":"2","key":"e_1_3_2_27_1","first-page":"293","article-title":"Geographic accessibility to clinical trials for advanced cancer in the United States","volume":"175","author":"Galsky M","year":"2015","unstructured":"Galsky M , StenslandK, McBrideRB. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA175(2), 293\u2013295 (2015).","journal-title":"JAMA"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-469"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510059"},{"key":"e_1_3_2_30_1","unstructured":"FDA . \u2018Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims\u2019 (2009). http:\/\/\/www.fdagov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282."},{"key":"e_1_3_2_31_1","volume-title":"Quality of life: the assessment, analysis and interpretation of patient-reported outcomes.","author":"Fayers P","year":"2013","unstructured":"Fayers P , MachinD. Quality of life: the assessment, analysis and interpretation of patient-reported outcomes.Wiley, Hoboken (2013)."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1038-2"},{"key":"e_1_3_2_33_1","unstructured":"FDA . Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry (2019). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/placebos-and-blinding-randomized-controlled-cancer-clinical-trials-drug-and-biological-products"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-18539-2"},{"key":"e_1_3_2_35_1","unstructured":"Deng W . Potential Unblinding due to Imbalance in Adverse Event Profiles (2018). http:\/\/onbiostatistics.blogspot.com\/2018\/10\/potential-unblinding-due-to-imbalance.html."},{"issue":"5","key":"e_1_3_2_36_1","first-page":"345","article-title":"Blinding: who, what, when, why, how?","volume":"53","author":"Karanicolas PJ","year":"2010","unstructured":"Karanicolas PJ , FarrokhyarF, BhandariM, KaranicolasPJ. Blinding: who, what, when, why, how?Can. J. Surg.53(5), 345\u2013348 (2010).","journal-title":"Can. J. Surg."},{"issue":"456","key":"e_1_3_2_37_1","first-page":"1","article-title":"Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials","volume":"15","author":"Kahan B","year":"2014","unstructured":"Kahan B , CroS, Dor\u00e9C. Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials15(456), 1\u20136 (2014).","journal-title":"Trials"},{"issue":"387","key":"e_1_3_2_38_1","first-page":"1","article-title":"Reducing the confusion and controversies around pragmatic trials: using the Cardiovascular Health Awareness Program (CHAP) trial as an illustrative example","volume":"16","author":"Thabane L","year":"2015","unstructured":"Thabane L , KaczorowskiJ, DolovichL. Reducing the confusion and controversies around pragmatic trials: using the Cardiovascular Health Awareness Program (CHAP) trial as an illustrative example. Trials16(387), 1\u20138 (2015).","journal-title":"Trials"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510059"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2021-0043"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_156686"},{"issue":"119","key":"e_1_3_2_42_1","first-page":"1","article-title":"Patient and public involvement (PPI) in UK surgical trials: a survey and focus groups with stakeholders to identify practices, views, and experiences","volume":"20","author":"Crocker J","year":"2019","unstructured":"Crocker J , Pratt-BoydenK, HislopJ. Patient and public involvement (PPI) in UK surgical trials: a survey and focus groups with stakeholders to identify practices, views, and experiences. Trials20(119), 1\u201315 (2019).","journal-title":"Trials"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1600"},{"key":"e_1_3_2_44_1","unstructured":"Treximo . 6 Challenges in Oncology Clinical Trials: Recruitment Enrollment & more (2020). https:\/\/treximo.com\/blog\/6-unique-challenges-hindering-oncology-clinical-trials\/."},{"issue":"122","key":"e_1_3_2_45_1","first-page":"S13063","article-title":"Why clinical trial outcomes fail to translate into benefits for patients","volume":"18","author":"Heneghan C","year":"2017","unstructured":"Heneghan C , GoldacreB, MahtaniK. Why clinical trial outcomes fail to translate into benefits for patients. Trials18(122), S13063\u2013S01 (2017).","journal-title":"Trials"},{"key":"e_1_3_2_46_1","unstructured":"James Lind Alliance . Top 10s of priorities for research. (2021). https:\/\/www.jla.nihr.ac.uk\/top-10-priorities\/."},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0096"},{"key":"e_1_3_2_48_1","unstructured":"van\u2019t Hoff W . \u2018A Patient-Centric Approach To Increase Recruitment And Retention In Clinical Trials\u2019 (2019). https:\/\/www.clinicalleader.com\/doc\/a-patient-centric-approach-to-increase-recruitment-and-retention-in-clinical-trials-0001"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4738"},{"issue":"57","key":"e_1_3_2_50_1","first-page":"1","article-title":"The reality of informed consent: empirical studies on patient comprehension\u2014systematic review","volume":"22","author":"Pietrzykowski T","year":"2021","unstructured":"Pietrzykowski T , SmilowskaK. The reality of informed consent: empirical studies on patient comprehension\u2014systematic review. Trials22(57), 1\u20138 (2021).","journal-title":"Trials"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2010.0675"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3453"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13497"},{"issue":"1","key":"e_1_3_2_54_1","first-page":"1","article-title":"Twenty years post-NIH Revitalization Act: renewing the case for enhancing minority participation in cancer clinical trials","volume":"23","author":"Chen MS","year":"2008","unstructured":"Chen MS Jr , LaraPN, DangJHT, PaternitiDA, KellyK. Twenty years post-NIH Revitalization Act: renewing the case for enhancing minority participation in cancer clinical trials. Bone23(1), 1\u20137 (2008).","journal-title":"Bone"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2055"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0123"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0423"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx798"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015997"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy064"},{"key":"e_1_3_2_61_1","unstructured":"Patient-Centered Outcome Research Institute . The Value of Engagement (2019). https:\/\/www.pcori.org\/engagement\/value-engagement."},{"key":"e_1_3_2_62_1","unstructured":"Gertz . Rules of engagement - redefining the sponsor-CRO relationship (2016). https:\/\/www.worldpharmaceuticals.net\/features\/featurerules-of-engagement---redefining-the-sponsor-cro-relationship-4944530\/"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.961"},{"issue":"4","key":"e_1_3_2_64_1","first-page":"259","article-title":"BRAF Mutation in Colorectal Cancer: An Enigmatic Target","volume":"39","author":"Eng C","year":"2021","unstructured":"Eng C . BRAF Mutation in Colorectal Cancer: An Enigmatic Target. Clin. Oncol.39(4), 259\u2013261 (2021).","journal-title":"Clin. Oncol."},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12465"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.35"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2017.10.005"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1226"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.2635"},{"key":"e_1_3_2_70_1","unstructured":"American Cancer Society . Cancer Treatment and Survivorship Facts Figures 2019 to 2021. GA USA (2019). https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/cancer-treatment-and-survivorship-facts-and-figures\/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-2019-x"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-0689"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-013-0312-8"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-018-0704-x"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1554"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2012.1176"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.11100"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21638"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.6125"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8687"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2639"},{"issue":"1","key":"e_1_3_2_82_1","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jgo.2013.09.064","article-title":"Overall treatment utility: a novel outcome measure to convey the balance of benefits and harms from cancer treatment","volume":"4","author":"Handforth C","year":"2013","unstructured":"Handforth C , HallP, MarshallH, SeymourM. Overall treatment utility: a novel outcome measure to convey the balance of benefits and harms from cancer treatment. J. Geriatr Oncol.4(Suppl. 1), S49 (2013).","journal-title":"J. Geriatr Oncol."},{"key":"e_1_3_2_83_1","unstructured":"Association of Community Cancer Centers . \u2018Multidisciplinary Approaches to Caring for Older Adults With Cancer (2019). https:\/\/www.accc-cancer.org\/home\/news-media\/press-releases\/news-template\/2019\/12\/16\/association-of-community-cancer-centers-calls-attention-to-importance-of-geriatric-assessment-in-caring-for-older-adults-with-cancer."},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.222"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy228"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2018.05.008"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-014-0697-8"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt474"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4553-T"},{"key":"e_1_3_2_90_1","unstructured":"Breast Cancer Research Foundation . Giving Patients a Voice in Medical Research (2020). https:\/\/www.bcrf.org\/how-patient-advocates-help-breast-cancer-researchers-bcrf"},{"key":"e_1_3_2_91_1","unstructured":"National Foundation for Cancer Research . About us (2020). https:\/\/www.nfcr.org\/about\/."},{"key":"e_1_3_2_92_1","unstructured":"American Cancer Society . Cancer Advocacy (2018). https:\/\/www.cancer.org\/about-us\/what-we-do\/advocacy.html."},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00446-3"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1177\/2168479015580384"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_156686"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.22.2970"},{"key":"e_1_3_2_97_1","unstructured":"National Cancer Institute . Find a cancer center (2019). https:\/\/www.cancer.gov\/research\/infrastructure\/cancer-centers\/find"},{"key":"e_1_3_2_98_1","first-page":"11","article-title":"Financial toxicity and equitable access to clinical trials","volume":"39","author":"Chino F","year":"2021","unstructured":"Chino F , ZafarY. Financial toxicity and equitable access to clinical trials. ASCO Educ. B.39, 11\u201318 (2021).","journal-title":"ASCO Educ. B."},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3924"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114048"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-4068-9"},{"key":"e_1_3_2_102_1","unstructured":"RCS . WilliamS. SurgicalInnovation New Techniquesand Technologies: A Guide to Good Practice (2019). https:\/\/www.rcseng.ac.uk\/standards-and-research\/standards-and-guidance\/good-practice-guides\/surgical-innovation\/"},{"key":"e_1_3_2_103_1","unstructured":"IOM . A National Cancer Clinical Trials System for the 21st Century Reinvigorating the NCI Cooperative Group Program Institute of Medicine (US) Committee on Cancer Clinical Trials and the NCI Cooperative Group Program. National Academies Press DC USA (2010)."},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0096"},{"key":"e_1_3_2_105_1","unstructured":"ASCO . ASCO\u2019s Blue print for transforming clinical and translational cancer research (2011). https:\/\/www.asco.org\/sites\/new-www.asco.org\/files\/content-files\/research-and-progress\/documents\/2011-blueprint-accelerating-progress-against-cancer.pdf"},{"key":"e_1_3_2_106_1","unstructured":"The Economist Intelligence Unit . The innovation imperative: the future of drug development part I: research methods and findings (2018). https:\/\/druginnovation.eiu.com\/wp-content\/uploads\/2019\/05\/Parexel-innovations-in-drug-development-part-1_V14.pdf"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd18.210006"},{"issue":"4","key":"e_1_3_2_108_1","first-page":"e214708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib L","year":"2021","unstructured":"Rahib L , WehnerM, MatrisianL, NeadK. Estimated projection of US cancer incidence and death to 2040. JAMA4(4), e214708 (2021).","journal-title":"JAMA"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa023"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21560"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1257\/jep.25.2.27"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1301"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.2165\/11539400-000000000-00000"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-0556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:47:24Z","timestamp":1719125244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-0556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":111,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.2217\/fon-2021-0556"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-0556","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}